Using the drop-down menu below, read about highlighted scientific news for patients from ASCO's Annual Meetings, Symposia, and medical journals for the past three years. You can select a specific year, meeting or publication, and/or a specific topic, such as a type of cancer. Selecting "All" will take you to a complete list of articles that appear under all categories.
This includes ASCO’s Journal of Clinical Oncology and its scientific meetings, including the ASCO Annual Meeting, a five-day meeting held each May/June. To read the Annual Meeting summaries compiled into a yearly newsletter, you can also review Research Round Up: News for Patients from the ASCO Annual Meeting.Don’t forget to check out audio podcasts and videos about this news, as well. And a list of upcoming Symposia can be found here. And, in addition to the highlighted studies below, thousands of scientific abstracts are released each year at different ASCO meetings. To search the entire collection of meeting abstracts, visit ASCO's website.
In a large, ongoing study, results indicate that two common treatment regimens approved by the U.S. Food and Drug Administration are equally effective for metastatic colorectal cancer. Metastatic colorectal cancer is cancer that has spread to other parts of the body.
Results from a large study show that the combination of lapatinib (Tykerb) and trastuzumab (Herceptin) plus chemotherapy after surgery is not more effective than only trastuzumab plus chemotherapy for women with early-stage, human epidermal receptor 2 (HER2)-positive breast cancer.
In a recent study, researchers found that the combination of olaparib and cediranib (Recentin) kept recurrent ovarian cancer from worsening for almost nine months longer than treatment with olaparib alone.
Results from a new study show that combining the targeted therapy ramucirumab (Cyramza) with standard chemotherapy lengthens the lives of patients with non-small cell lung cancer (NSCLC). Targeted therapy is a treatment that targets the cancer’s specific genes, proteins, or the tissue environment that contributes to cancer growth and survival.
Early results from an ongoing study show that ibrutinib (Imbruvica) keeps relapsed chronic lymphocytic leukemia (CLL) from worsening for longer than ofatumumab (Arzerra), a standard treatment option for relapsed or refractory CLL.
Results from a recent study show that the drug lenvatinib could become a new, effective treatment option for patients with differentiated thyroid cancer that is resistant to standard radioiodine (RAI) therapy.
A new study demonstrates the benefits of a phone-based palliative care support program for caregivers of people with advanced cancer. The results suggest that the earlier palliative care services are introduced to caregivers, the better they will be able to cope with the caregiving experience.
According to new research, people who are expected to live less than a year can safely stop taking cholesterol-lowering drugs, known as statins, without shortening their lives. In fact, discontinuing statins provided a number of important benefits, including reducing symptoms, having to take fewer pills, and improving overall quality of life.
Results from a recent phase III clinical trial show that women who took goserelin (Zoladex) with chemotherapy for early-stage, hormone receptor-negative breast cancer were 64% less likely to develop premature ovarian failure, also called early menopause, compared with women who received chemotherapy alone.
According to new findings from a phase III clinical trial, women taking zoledronic acid (Zometa) for breast cancer that has spread to the bone, called metastases, can safely scale back to a once-every-three-months schedule after finishing a year of monthly treatments.